iBio bought the remaining 30% of its subsidiary iBio CDMO, which holds the exclusive rights to manufacture drugs using the FastPharming system in the United States. iBio also purchased from Eastern Capital Limited a manufacturing facility whose facilities it had previously leased. iBio paid $28 million in cash and issued warrants to purchase 1,000,000 of its shares for $750,000.